Article Text

PDF
Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease
  1. R McNeill1,
  2. G M Sare1,
  3. M Manoharan2,
  4. H J Testa2,
  5. D M A Mann1,
  6. D Neary1,
  7. J S Snowden1,
  8. A R Varma1
  1. 1Department of Neurology, Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford, Manchester, UK
  2. 2Nuclear Medicine, Manchester Royal Infirmary, Manchester, UK
  1. Correspondence to:
 Dr A R Varma
 Neurology Department, Greater Manchester Neurosciences Centre, Hope & NMGH Hospitals, Salford M6 8HD, UK;anoop.varma{at}srht.nhs.uk

Abstract

Background: Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are the commonest causes of presenile dementia. In the absence of a biological marker, diagnosis is reliant on clinical evaluation. Confirmation is often sought from neuroimaging, including single-photon emission computed tomography (SPECT). Most previous SPECT studies lack pathological validation.

Aim: To examine the accuracy of SPECT in differentiating FTD from AD in patients with subsequent pathological confirmation.

Methods: Technetium-99-labelled hexamethyl propylene amine oxime SPECT images obtained at initial evaluation in 25 pathologically confirmed cases of FTD were examined. These images were visually rated by an experienced blinded nuclear medicine consultant and compared with those of 31 patients with AD, also with pathological validation.

Results: A reduction in frontal cerebral blood flow (CBF) was more common in FTD and was of diagnostic value (sensitivity 0.8, specificity 0.65 and likelihood ratio (LR) 2.25; 95% CI 1.35 to 3.77). A pattern of bilateral frontal CBF reduction without the presence of associated bilateral parietal CBF change is diagnostically more accurate (sensitivity 0.80, specificity 0.81 and +LR 4.13, 95% CI 1.96 to 8.71). Diagnostic categorisation (FTD or AD) on the basis of SPECT alone was less accurate than clinical diagnosis (based on neurology and detailed neuropsychological evaluation). One patient with FTD was initially clinically misdiagnosed as AD, owing to the lack of availability of full neuropsychological assessment. However, SPECT correctly diagnosed this patient, providing a diagnostic gain of 4%.

Conclusion: Technetium-99-labelled hexamethyl propylene amine oxime SPECT CBF patterns provide valuable information in the diagnosis of FTD and AD. These data can be better used as an adjunct to clinical diagnosis if pathology is to be correctly predicted in life.

  • AD, Alzheimer’s disease
  • CBF, cerebral blood flow
  • FTD, frontotemporal dementia
  • MMSE, Mini Mental State Examination
  • SPECT, single-photon emission computed tomography

Statistics from Altmetric.com

Footnotes

  • Published Online First 8 December 2006

  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.